Engineered T cells and their therapeutic applications in autoimmune diseases

被引：19
作者：
Bao, Lei [1 ]
Bo, Xiao-Chen [1 ]
Cao, Huai-Wen [1 ]
Qian, Chen [1 ]
Wang, Zeng [1 ]
Li, Bin [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai 200025, Peoples R China
来源：
ZOOLOGICAL RESEARCH | 2022年 / 43卷 / 02期
基金：
国家重点研发计划; 中国国家自然科学基金;
关键词：
Chimeric antigen receptor T cells; Cell immunotherapy; Autoimmune diseases; SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-CELL; RHEUMATOID-ARTHRITIS; PEMPHIGUS-VULGARIS; CD19; CAR; CLINICAL DEVELOPMENT; MICROSCOPIC COLITIS; GENE-TRANSFER; IN-VITRO; ANTIGEN;
D O I：
10.24272/j.issn.2095-8137.2021.363
中图分类号：
Q95 [动物学];
学科分类号：
071002 ;
摘要：
Chimeric antigen receptor T cells (CAR-T cells) are engineered recombinant T cells, which were initially used to treat hematopoietic malignancies and are now widely used in the treatment of various diseases. Considering their intrinsic targeting efficiency, CAR-T cells show considerable potential in the treatment of autoimmune diseases. Furthermore, regulatory T cells (Treg), a subset of CD4 T cells exhibiting immunosuppressive functions, have attracted increasing attention regarding CAR-Treg cell production. In this review, we report on recent developments in preclinical and clinical studies on CAR-T cells in autoimmune diseases and provide an outlook on opportunities and challenges of CAR-T application in such diseases.
引用
收藏
页码：150 / 165
页数：16
相关论文
共 146 条
[11]   Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells [J].
Blat, Dan ;
Zigmond, Ehud ;
Alteber, Zoya ;
Waks, Tova ;
Eshhar, Zelig .
MOLECULAR THERAPY, 2014, 22 (05) :1018-1028
[12]   Type 1 diabetes immunotherapy using polyclonal regulatory T cells [J].
Bluestone, Jeffrey A. ;
Buckner, Jane H. ;
Fitch, Mark ;
Gitelman, Stephen E. ;
Gupta, Shipra ;
Hellerstein, Marc K. ;
Herold, Kevan C. ;
Lares, Angela ;
Lee, Michael R. ;
Li, Kelvin ;
Liu, Weihong ;
Long, S. Alice ;
Masiello, Lisa M. ;
Vinh Nguyen ;
Putnam, Amy L. ;
Rieck, Mary ;
Sayre, Peter H. ;
Tang, Qizhi .
SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (315)
[13]   Genetics, pathogenesis and clinical interventions in type 1 diabetes [J].
Bluestone, Jeffrey A. ;
Herold, Kevan ;
Eisenbarth, George .
NATURE, 2010, 464 (7293) :1293-1300
[14]   Toxicity and management in CAR T-cell therapy [J].
Bonifant, Challice L. ;
Jackson, Hollie J. ;
Brentjens, Renier J. ;
Curran, Kevin J. .
MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 :16011
[15]   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].
Bonini, C ;
Ferrari, G ;
Verzeletti, S ;
Servida, P ;
Zappone, E ;
Ruggieri, L ;
Ponzoni, M ;
Rossini, S ;
Mavilio, F ;
Traversari, C ;
Bordignon, C .
SCIENCE, 1997, 276 (5319) :1719-1724
[16]   Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells [J].
Bour-Jordan, Helene ;
Bluestone, Jeffrey A. .
IMMUNOLOGICAL REVIEWS, 2009, 229 :41-66
[17]  
Breslin Sheila, 2007, Clin J Oncol Nurs, V11, P37, DOI 10.1188/07.CJON.S1.37-42
[18]   Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma [J].
Brudno, Jennifer N. ;
Lam, Norris ;
Vanasse, Danielle ;
Shen, Yueh-wei ;
Rose, Jeremy J. ;
Rossi, John ;
Xue, Allen ;
Bot, Adrian ;
Scholler, Nathalie ;
Mikkilineni, Lekha ;
Roschewski, Mark ;
Dean, Robert ;
Cachau, Raul ;
Youkharibache, Philippe ;
Patel, Rashmika ;
Hansen, Brenna ;
Stroncek, David F. ;
Rosenberg, Steven A. ;
Gress, Ronald E. ;
Kochenderfer, James N. .
NATURE MEDICINE, 2020, 26 (02) :270-+
[19]   Modulation of T cell function by TCR/pMHC binding kinetics [J].
Carreño, LJ ;
González, PA ;
Kalergis, AM .
IMMUNOBIOLOGY, 2006, 211 (1-2) :47-64
[20]   Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases [J].
Chen, Yuehong ;
Sun, Jianhong ;
Liu, Huan ;
Yin, Geng ;
Xie, Qibing .
JOURNAL OF IMMUNOLOGY RESEARCH, 2019, 2019
12345678910